Huperizine-A (Biscayne Pharmaceuticals)

N/A

Report date: 2026/02/02 10:59:03

Base Information

Drug NameHuperizine-A (Biscayne Pharmaceuticals)
Drug Alias NameCerebraHup-ABIS-001INS-001BIS-001-ER +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetylcholinesterase inhibitorsGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptorAcetylcholinesterase
Therapy Area/IndicationsSeizuresEpilepsy, Complex Partial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHarvard University
China Registration ClassN/A

Develop Information

Active CompaniesSupernus Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSeizures
Inactive IndicationsEpilepsy, Complex Partial

Other Information

ATC CodeN/A
Related LinksN/A